We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.38B
AUM Growth
+$319M
Cap. Flow
-$50.3M
Cap. Flow %
-0.6%
Top 10 Hldgs %
33.94%
Holding
161
New
20
Increased
28
Reduced
35
Closed
14

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$304M
2
ELV icon
Elevance Health
ELV
+$123M
3
XRAY icon
Dentsply Sirona
XRAY
+$102M
4
AGN
Allergan plc
AGN
+$95.1M
5
INSP icon
Inspire Medical Systems
INSP
+$78.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$185M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$154M
3
ABBV icon
AbbVie
ABBV
+$145M
4
THC icon
Tenet Healthcare
THC
+$119M
5
BMY icon
Bristol-Myers Squibb
BMY
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.69%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$106M 1.26%
2,330,870
– –
XRAY icon
27
Dentsply Sirona
XRAY
$2.78B
$105M 1.25%
2,393,500
+2,168,500
+964% +$102M
NVRO
28
DELISTED
NEVRO CORP.
NVRO
$101M 1.2%
1,260,091
– –
BOLD
29
DELISTED
Audentes Therapeutics, Inc
BOLD
$99.9M 1.19%
2,615,000
-907,100
-26% -$33.6M
LOXO
30
DELISTED
Loxo Oncology, Inc
LOXO
$93.3M 1.11%
538,000
-403,000
-43% -$60.6M
SEM
31
DELISTED
Select Medical
SEM
$92.1M 1.1%
9,417,715
– –
JNJ icon
32
Johnson & Johnson
JNJ
$646B
$91.7M 1.09%
756,000
+290,700
+62% +$36.3M
INSP icon
33
Inspire Medical Systems
INSP
$1.49B
$87.2M 1.04%
+2,444,221
New +$78.9M
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$82.2M 0.98%
4,900,900
– –
ILMN icon
35
Illumina
ILMN
$29.1B
$79.5M 0.95%
292,466
– –
DCPH
36
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$78.9M 0.94%
2,005,700
+472,800
+31% +$13.9M
BLUE
37
DELISTED
bluebird bio
BLUE
$76.6M 0.91%
37,689
+11,009
+41% +$25.1M
IOVA icon
38
Iovance Biotherapeutics
IOVA
$2.02B
$71M 0.85%
5,548,326
– –
INSM icon
39
Insmed
INSM
$22.5B
$69.2M 0.83%
2,927,891
– –
CRVS icon
40
Corvus Pharmaceuticals
CRVS
$1.1B
$65.5M 0.78%
5,967,584
– –
VRAY
41
DELISTED
ViewRay, Inc.
VRAY
$65.5M 0.78%
9,458,567
– –
ACAD icon
42
Acadia Pharmaceuticals
ACAD
$4.45B
$65.4M 0.78%
4,282,400
+941,700
+28% +$16.8M
RYTM icon
43
Rhythm Pharmaceuticals
RYTM
$7.35B
$64.6M 0.77%
2,065,000
-836,295
-29% -$22.9M
SHPG
44
DELISTED
Shire pic
SHPG
$60.2M 0.72%
356,608
-293,700
-45% -$47.4M
SRPT icon
45
Sarepta Therapeutics
SRPT
$1.66B
$59.8M 0.71%
452,600
+131,000
+41% +$12.4M
IRWD icon
46
Ironwood Pharmaceuticals
IRWD
$598M
$56M 0.67%
3,497,525
– –
ISRG icon
47
Intuitive Surgical
ISRG
$128B
$52.9M 0.63%
331,500
+25,500
+8% +$3.89M
UHS icon
48
Universal Health Services
UHS
$10.2B
$51.6M 0.62%
463,300
-309,600
-40% -$36.3M
XTNT icon
49
Xtant Medical Holdings
XTNT
$59.1M
$51.1M 0.61%
9,207,012
– –
HRTX icon
50
Heron Therapeutics
HRTX
$92.3M
$51.1M 0.61%
1,315,100
+175,300
+15% +$5.58M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2018 Portfolio in Review

As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
  • OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
  • OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
  • OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
  • OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
  • OrbiMed opened 20 new positions and closed 14 in Q2 2018.
  • OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.